• ABOUT US
  • SCIENCE
  • FACILITY
  • INVESTORS
    • Media
    • Notice
    • Public Disclosures
    • Stock Information
    • Financials
  • ESG
    • ESG Management
    • Archive
  • CONTACT
  • ABOUT US
  • SCIENCE
  • FACILITY
  • INVESTORS
    • Media
    • Notice
    • Public Disclosures
    • Stock Information
    • Financials
  • ESG
    • ESG Management
    • Archive
  • CONTACT

INVESTORS

[머니투데이] 큐로셀, 국산 최초 CAR-T 승인 초읽기…상업화 넘어 적응증 확장도 순항

2025/08/11

큐로셀, 국산 최초 CAR-T 승인 초읽기…상업화 넘어 적응증 확장도 순항 – 머니투데이

Prev큐로셀, 성인 ALL 대상 ‘안발셀’ IND 변경 신청… 임상 2상 개시 목적
Next[한국경제] 큐로셀 “루푸스병 신약에 도전장”…토종 맞춤형 세포치료제 임상에 뛰어들다
Copyright 2023. Curocell Inc. All Rights Reserved.
Created by PRESSCAT
  • ABOUT US
  • SCIENCE
  • FACILITY
  • INVESTORS
    • Media
    • Notice
    • Public Disclosures
    • Stock Information
    • Financials
  • ESG
    • ESG Management
    • Archive
  • CONTACT
  • ABOUT US
  • SCIENCE
  • FACILITY
  • INVESTORS
    • Media
    • Notice
    • Public Disclosures
    • Stock Information
    • Financials
  • ESG
    • ESG Management
    • Archive
  • CONTACT
Copyright 2023. Curocell Inc. All Rights Reserved.